Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2019

01-05-2019 | Original Article

Hepatitis C Virus Entry into Macrophages/Monocytes Mainly Depends on the Phagocytosis of Macrophages

Authors: Yuan Liu, Wenbo Wang, Ziying Zou, Zonghai Hu, Quanshui Fan, Jie Xiong

Published in: Digestive Diseases and Sciences | Issue 5/2019

Login to get access

Abstract

Background

Hepatitis C virus (HCV) has been classified as a strictly hepatotropic pathogen for a long time, and hepatocytes are target cells for HCV infection. More and more studies showed non-liver cells supported HCV entry and replication, such as macrophages. The mechanisms of HCV entry into macrophages are still not clear.

Aims

This study aims to determine the way of HCV entry into macrophages.

Methods

Cell culture-derived infectious HCV particles (HCVcc) were prepared using Huh7 cells transfected with HCV RNA. CD81-knockdown cells were obtained through siRNA transfection. HCV RNA levels were determined by RT-qPCR. Flow cytometry analyses were used to determine cell surface levels of CD11b, CD68, and CD81. ELISA and western blotting were performed to quantify the protein levels of IL-1β, IL-6, and TNF-α. Phagocytic ability was determined by neutral red uptake assay.

Results

CD81 knockdown could not inhibit HCVcc entry into macrophages. The entry of HCV into macrophages could not be blocked by pooled IgG from chronic hepatitis C patient’s sera. Macrophages derived from THP-1 cells displayed stronger phagocytic capacity, which also swallowed more HCV RNA. Treatment of macrophages with endocytic inhibitor, methyl-β-cyclodextrin, decreased the internalization of HCV. HCV uptake by macrophages was related to the reorganization of F-actin cytoskeleton and PI3Ks activation. HCV infection significantly increased the expression of IL1β and IL6 in macrophages and promoted apoptosis of macrophages.

Conclusions

HCV entry into macrophages mainly depends on phagocytosis of macrophages.
Appendix
Available only for authorised users
Literature
7.
go back to reference Rodríguez-Iñigo E, Casqueiro M, Navas S, Bartolomé J, Pardo M, Carreño V. Fluorescent “in situ” hybridization of hepatitis C virus RNA in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Med Virol. 2000;60:269–274.CrossRefPubMed Rodríguez-Iñigo E, Casqueiro M, Navas S, Bartolomé J, Pardo M, Carreño V. Fluorescent “in situ” hybridization of hepatitis C virus RNA in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Med Virol. 2000;60:269–274.CrossRefPubMed
8.
go back to reference Radkowski M, Kubicka J, Kisiel E, et al. Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication. Blood. 2000;95:3986–3989.PubMed Radkowski M, Kubicka J, Kisiel E, et al. Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication. Blood. 2000;95:3986–3989.PubMed
16.
go back to reference Wang W, Guan M, Liu Y, et al. Alanine scanning mutagenesis of hepatitis C virus E2 cysteine residues: Insights into E2 biogenesis and antigenicity. Virology. 2014;448:229–237.CrossRefPubMed Wang W, Guan M, Liu Y, et al. Alanine scanning mutagenesis of hepatitis C virus E2 cysteine residues: Insights into E2 biogenesis and antigenicity. Virology. 2014;448:229–237.CrossRefPubMed
Metadata
Title
Hepatitis C Virus Entry into Macrophages/Monocytes Mainly Depends on the Phagocytosis of Macrophages
Authors
Yuan Liu
Wenbo Wang
Ziying Zou
Zonghai Hu
Quanshui Fan
Jie Xiong
Publication date
01-05-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5401-0

Other articles of this Issue 5/2019

Digestive Diseases and Sciences 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.